MabVax Therapeutics

MabVax Therapeutics

MabVax Therapeutics

MabVax is a biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies.
Founded
2006
Raised
$22.9M
Follow us
Alexa global traffic share
Twitter followers
Latest funding Show all
$1,300,000
Post-IPO equity - 2017
$11,600,000
Post-IPO equity - 2015
Team Size
2
Employees
Xconomy

With Losses Mounting, MabVax Therapeutics Looks to Sell Off Assets